New Delhi: As per a news study, chemotherapy-induced cardiomyopathy reacts more on men than women.


COMMERCIAL BREAK
SCROLL TO CONTINUE READING

"Cancer patients are living longer because of improved treatment but the side effects of treatment include cardiovascular morbidity and mortality," said lead author Dr Iwan Harries, from the University of Bristol, UK.


A 2016 European Society of Cardiology (ESC) position paper on cardio-oncology described female sex as a risk factor for developing cardiotoxicity from chemotherapy.Dr Harries said, "The data largely originates from paediatric populations and, in contrast, animal studies report male susceptibility to cardiomyopathy.


"This retrospective observational study in adults investigated whether there was a sex effect on chemotherapy-induced cardiomyopathy.


The researchers identified all patients over a six year period that received potentially cardiotoxic chemotherapy, were referred for CMR, and were found to have impaired left ventricular function (chemotherapy-induced cardiomyopathy).


Patients were excluded if they had another condition that could have contributed to the cardiomyopathy such as ischaemic heart disease, valvular heart disease, family history of cardiomyopathy, or excess alcohol consumption.


The study included 76 patients (45 women and 31 men). Data was collected on baseline demographics and comorbidities.


Details of the cancer treatment were recorded, including the type of chemotherapy, dose of chemotherapy, and the interval between receiving treatment and having the CMR scan.


CMR scans provided information on left and right ventricular function, cardiac volumes, and tissue characteristics.


To assess the potential impact of gender on the development of chemotherapy-induced cardiomyopathy, the researchers conducted a multivariate regression analysis correcting for baseline differences between men and women including age, body surface area, comorbidities, and treatment.


(With ANI inputs)